Niagen Bioscience Inc

Niagen Bioscience Inc maintains a strong liquidity position, with a current ratio of 4.86, indicating the company has nearly five times more current assets than current liabilities. The company has no long-term debt, and its liquidity risk is assessed as low. The price-to-book ratio of 3.95 suggests the market is valuing the company at a premium to its book value, which may reflect expectations of future growth or intangible assets. The company's profitability is robust, with a return on equity (ROE) of 22.71% and a return on assets (ROA) of 16.34%, both of which exceed the typical thresholds for strong performance in the biotechnology sector. The net income of $17.38 million on revenue of $129.42 million indicates a net margin of approximately 13.43%, which is a strong indicator of efficient cost management and pricing power. Niagen Bioscience Inc operates in a single business segment, with no disclosed geographic diversification in the provided data. The company's revenue is entirely attributed to its core product, nicotinamide riboside, and there is no indication of revenue concentration risk in the data. The company's growth trajectory is positive, with a price-to-earnings (P/E) ratio of 17.41, which is in line with the biotechnology sector's average. Analysts have set a mean price target of $13.60, significantly higher than the current market price of $3.80, indicating strong growth expectations. The free cash flow of $17.88 million suggests the company is generating sufficient cash to support operations and potentially fund future growth initiatives. The risk assessment for Niagen Bioscience Inc is favorable, with low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the dilution risk is assessed as low. The absence of long-term debt and the strong equity position further reduce financial risk. Recent events and disclosures indicate a stable financial position, with no significant negative developments reported. The company's capital expenditure of -$292,000 suggests a reduction in capital spending, which may indicate a shift in strategic focus or a more conservative approach to capital allocation. The strong analyst sentiment, with a mean recommendation of 1.60 (favoring strong buy), supports the view that the company is well-positioned for future growth.